Patrick K. Reville

Hematology

34 Maple St
Norwalk, CT 06850

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance.

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry.

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry.

Journal: Blood immunology & cellular therapy

Published: May 11, 2026

Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

Correction: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

Journal: Frontiers in oncology

Published: March 05, 2026

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: December 10, 2025

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 13, 2025

A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion.

Journal: Frontiers in oncology

Published: April 04, 2025

Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.

Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.

Journal: Leukemia & lymphoma

Published: March 31, 2025

Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML.

Integrative spatial multi-omics reveal niche-specific inflammatory signaling and differentiation hierarchies in AML.

Journal: iScience

Published: March 03, 2025

Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.

Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.

Journal: American journal of hematology

Published: January 23, 2025

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 18, 2025

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Journal: Blood cancer journal

Published: December 24, 2024

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: November 25, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026